Telix Pharmaceuticals (TLX) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Commercial base and growth
2026 imaging revenue ~ $1bn; generated >$400m in cash for R&D, infrastructure and supply-chain investment.
Illuccix and Gozellix serve 22 countries and hold just over 40% market share; the prostate business grew >25% in 2026.
Q3 was flat as planned and FY guidance was reiterated; a strong Q4 exit supported expectations for continued growth, with 5%-7% underlying PSMA market growth.
Management expects 25% of PSMA scans to be performed under urology supervision within three years, supported by practice-based pharmacy and scanner infrastructure.
Commercial pipeline and label expansion
BYPASS phase III enrollment is complete; data are expected in late Q1 or early Q2 2027, with potential to add nearly 1m U.S. scans and a fast-track, rolling NDA pathway.
BYPASS aims to use PET plus MRI to guide biopsy decisions; management cited 1-1.2m U.S. template biopsies annually and 200,000-300,000 men who avoid the current process.
Zircaix BLA resubmission is expected before end-2026; approval is currently expected toward the end of H1 2027, following resolution of FDA manufacturing consultations.
Pixclara has a broad glioblastoma label, reimbursement begins in January, and uptake has been swift; management sees a few-hundred-million-dollar U.S. opportunity, potentially exceeding $500m with CNS metastases.
ITM transaction and supply strategy
The ITM transaction is agreed, with closing targeted before end-2026 subject to conditions; management highlighted the addition of ~800 radiopharma experts.
ITM brings global, terabecquerel-scale lutetium supply and Actineer actinium capabilities; management cited 42 mid- or late-stage assets requiring lutetium and emphasized supply security.
ITM-11 could advance the therapeutics transition by ~18 months versus the prior late-2028 trajectory; its long shelf life and distribution flexibility support commercial reach.
ITM-11 label-expansion readouts in second- and third-line GEP-NET and lung NET are expected in 2027.
Latest events from Telix Pharmaceuticals
- BiPASS data and Pixclara reimbursement milestones set up key 2027 growth catalysts.TLX
Bell Potter Healthcare Conference - FY26 guidance and ITM integration underpin a 2027 growth step-up.TLX
CMD 2026 - Revenue rose 214%, turning FY2023 profitable as cash flow funded pipeline growth.TLX
H2 2023 - Revenue rose 19% YoY as Pixclara approval and the ITM merger advanced growth plans.TLX
Q3 2026 TU - Late-stage pipeline, global expansion, and strategic deals drive radiopharma leadership.TLX
R&D Day 2026 - US$1.65B merger creates a global radiopharma leader with EBITDA positivity targeted by 2027.TLX
M&A announcement - Imaging-driven growth funds late-stage trials in urology and neuro-oncology, with major data ahead.TLX
H.C. Wainwright 28th Annual Global Investment Conference - FDA approval, pipeline expansion, and integrated distribution drive radiopharma leadership.TLX
Morgan Stanley 24th Annual Global Healthcare Conference - Revenue up 22% to $477.3M, net profit $38.3M, margin and pipeline gains drive strong outlook.TLX
H1 2026